RespireRx Pharmaceuticals Announces Collaboration with University College London (UCL)
Thursday, April 06, 2023
RespireRx Pharmaceuticals announced that it has entered into a material transfer agreement with University College London (UCL).
As part of the collaboration, the RespireRx research team will be working to study the possibility of using CX1739, RespireRx’s lead clinical AMPAkine, for the treatment of a major class of GRIA disorders.
The ultimate goal of this collaboration is to test CX1739 in patients with specific variants which indicates a decline in function of the AMPA receptor. Positive therapeutic effects with RespireRx’s AMPAkines already have been reported in animal mutations modelling related disorders such as Pompe that also suffer from declines in AMPA receptor functioning. AMPAkines may have the potential to treat a broad range of patients suffering from AMPA receptor dysfunction.
It is very important to characterize the properties of AMPA receptor variants that underlie diversity symptoms of children with GRIA disease to better determine which medications may work as possible treatments. The use of AMPAkine CX1739, boosts AMPA receptor function, to determine on a molecular level its potential as a precision therapy for children with GRIA Disorder, for whom no truly effective treatment presently exists.
